Estrogens Impair Antitumor Immunity By Promoting The Accumulation Of Myeloid-Derived Suppressor Cells by Svoronos, Nikolaos
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2016
Estrogens Impair Antitumor Immunity By
Promoting The Accumulation Of Myeloid-Derived
Suppressor Cells
Nikolaos Svoronos
University of Pennsylvania, nikos.svoronos@gmail.com
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Cell Biology Commons, Endocrinology
Commons, Endocrinology, Diabetes, and Metabolism Commons, Immunology and Infectious
Disease Commons, and the Medical Immunology Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2600
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Svoronos, Nikolaos, "Estrogens Impair Antitumor Immunity By Promoting The Accumulation Of Myeloid-Derived Suppressor Cells"
(2016). Publicly Accessible Penn Dissertations. 2600.
https://repository.upenn.edu/edissertations/2600
Estrogens Impair Antitumor Immunity By Promoting The Accumulation
Of Myeloid-Derived Suppressor Cells
Abstract
Estrogens are pleiotropic steroid hormones with pro- and anti-inflammatory effects that influence
autoimmune disease and pregnancy. Both autoimmunity and pregnancy are similar to cancer with regard to
the immune system. In established tumors, as is the case in autoimmune disease and pregnancy, the host is
exposed to self or allogeneic antigens, which are capable of eliciting immune responses. However, for
pregnancies to remain viable, autoimmune disease patients survive, and tumors to persist, the immune system
must be at least partially tolerized to these challenges. Therefore, I hypothesize that, just as they appear to
influence pregnancy and autoimmunity, estrogens’ ability to mediate inflammation and the resulting immune
response is a crucial factor in tumor progression. Clinically, antiestrogens are effective adjuvant therapy in
estrogen-dependent, receptor (ER) positive breast cancer; however, little is known about their potential role
in cancers that are not thought to be estrogen-dependent, such as ovarian cancer. Outside of its direct
proliferative effect in ER+ breast tumors, little is known about the effect of estrogen signaling on the tumor
microenvironment, despite normal cell ER positivity in a variety of tumors. Using immunocompetent mouse
models, we demonstrate that systemic estrogen levels have an important effect on antitumor immunity.
Independent of neoplastic cell signaling, estrogens promote tumor progression by directly and indirectly
suppressing antitumor T cell responses. Estrogen-driven decreases in antitumor T cell effector activity
correspond with a large, cell-intrinsic increase in monocytic and granulocytic myeloid-derived suppressor
cells (MDSCs). We show that estrogen signaling increases responsiveness to tumor-initiated inflammatory
signals to augment STAT3 activation during myeloid cell differentiation. Estrogen increases the expression of
activating kinases, such as Jak2, in bone marrow progenitor cells thus priming the host to respond to tumor-
driven IL-6 by producing more MDSCs. Without estrogen signaling, MDSC differentiation and suppressive
activity is greatly diminished. Therefore, estrogens are able to play an important role in potentiating a
suppressive ovarian tumor microenvironment. This work suggests that antiestrogens have clinical potential in
a wide variety of tumors, especially in combination with immunotherapies or chemotherapies targeting
pathways critical for MDSC differentiation.
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ABSTRACT 
 
ESTROGENS IMPAIR ANTITUMOR IMMUNITY BY PROMOTING THE 
ACCUMULATION OF MYELOID-DERIVED SUPPRESSOR CELLS 
Nikolaos Svoronos 
José R. Conejo-Garcia, MD, PhD 
 
Estrogens are pleiotropic steroid hormones with pro- and anti-inflammatory effects that 
influence autoimmune disease and pregnancy.  Both autoimmunity and pregnancy are 
similar to cancer with regard to the immune system.  In established tumors, as is the case 
in autoimmune disease and pregnancy, the host is exposed to self or allogeneic antigens, 
which are capable of eliciting immune responses.  However, for pregnancies to remain 
viable, autoimmune disease patients survive, and tumors to persist, the immune system 
must be at least partially tolerized to these challenges.  Therefore, I hypothesize that, just 
as they appear to influence pregnancy and autoimmunity, estrogens’ ability to mediate 
inflammation and the resulting immune response is a crucial factor in tumor progression.  
Clinically, antiestrogens are effective adjuvant therapy in estrogen-dependent, receptor 
(ER) positive breast cancer; however, little is known about their potential role in cancers 
that are not thought to be estrogen-dependent, such as ovarian cancer.  Outside of its 
direct proliferative effect in ER+ breast tumors, little is known about the effect of 
estrogen signaling on the tumor microenvironment, despite normal cell ER positivity in a 
variety of tumors.  Using immunocompetent mouse models, we demonstrate that 
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systemic estrogen levels have an important effect on antitumor immunity.  Independent 
of neoplastic cell signaling, estrogens promote tumor progression by directly and 
indirectly suppressing antitumor T cell responses.  Estrogen-driven decreases in 
antitumor T cell effector activity correspond with a large, cell-intrinsic increase in 
monocytic and granulocytic myeloid-derived suppressor cells (MDSCs).  We show that 
estrogen signaling increases responsiveness to tumor-initiated inflammatory signals to 
augment STAT3 activation during myeloid cell differentiation.  Estrogen increases the 
expression of activating kinases, such as Jak2, in bone marrow progenitor cells thus 
priming the host to respond to tumor-driven IL-6 by producing more MDSCs.  Without 
estrogen signaling, MDSC differentiation and suppressive activity is greatly diminished.  
Therefore, estrogens are able to play an important role in potentiating a suppressive 
ovarian tumor microenvironment.  This work suggests that antiestrogens have clinical 
potential in a wide variety of tumors, especially in combination with immunotherapies or 
chemotherapies targeting pathways critical for MDSC differentiation. 
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CHAPTER 1 
 
 
 
GENERAL INTRODUCTION 
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Ovarian cancer 
 In 2012, ovarian cancer was diagnosed worldwide in 238,700 women and was 
responsible for 151,900 deaths (Torre et al. 2015).  Although ovarian cancer is relatively 
uncommon and only comprises 2.6% of cancer diagnoses among US women, at 5.1% it is 
responsible for a disproportionate number of female cancer deaths (Siegel, Miller, and 
Jemal 2016).  Ovarian cancer is the fifth leading cause of cancer deaths among US 
women and is the deadliest gynecological malignancy.  Because currently there are no 
consensus screening guidelines for early detection, ovarian cancer has been called the 
“silent killer.”  At diagnosis, 60% of ovarian cancers have already progressed to distant 
disease, which carries a dismal five-year survival rate of 28% (Siegel, Miller, and Jemal 
2016). 
 Treatment for ovarian cancer typically starts with surgery for staging and 
cytoreduction.  Standard staging includes total extrafascial hysterectomy with bilateral 
salpingo-oophorectomy and dissection of pelvic and paraaortic lymph nodes (Mann, 
Chalas, and Valea 2014).  Typically, omantectomy and cytology of the diaphragm are 
also performed for disease staging.  Cytoreductive surgery is then performed to remove 
all grossly visible tumor nodules found within the peritoneal cavity.  In many cases, 
cytoreductive surgery is suboptimal due to disease involvement of unresectable tissue, 
such as bowel, or is limited by the patient’s ability to tolerate such an invasive surgery.  
Additionally, surgery alone cannot remove micrometastases.  Therefore, in addition to 
surgery, patients are also given adjuvant chemotherapy.  The most common first-line 
regimen is a combination of platinum plus taxane therapies, such carboplatin plus 
paclitaxel (Herzog and Armstrong 2016). 
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 As evinced by its five-year survival rate of 28%, despite surgery and 
chemotherapy, most ovarian cancers with distant disease at diagnosis will recur and 
ultimately result in death.  Therefore, there is great need for a better understanding of the 
biology of ovarian cancer to facilitate the development of new therapies.  Of note, Zhang 
et al. found that ovarian tumors with tumor-infiltrating lymphocytes correlate with 
significantly increased survival (L. Zhang et al. 2003).  This discovery suggests that the 
tumor microenvironment plays a critical role in ovarian cancer progression, as has been 
demonstrated in other cancers.   
 
Composition of the tumor microenvironment 
Cancers begin as neoplastic cells characterized by uncontrolled cell growth 
following oncogenic transformation.  Over time, neoplastic cells continue to proliferate 
and become less differentiated, ultimately giving rise to carcinomas in situ.  Upon 
acquiring an invasive phenotype, such as via epithelial-mesenchymal transition (Ye and 
Weinberg 2015), tumors are able to metastasize to distal locations, ultimately resulting in 
death.  It is now evident that the progression of tumors from benign neoplasias to 
malignant, metastatic cancers depends on the accumulation of non-neoplastic, normal 
cells comprising the tumor microenvironment and pre-metastatic niche (Figure 1.1) 
(Sceneay, Smyth, and Möller 2013; Hanahan and Weinberg 2011). 
Non-neoplastic cells in the tumor microenvironment include fibroblasts, 
endothelial cells, pericytes, and leukocytes in addition to the normal, untransformed cells 
from which neoplastic cells were originally derived.  Each of these cell types is capable 
of playing a critical role in primary tumor growth and metastasis.  Fibroblasts provide 
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cytokines, extracellular matrix, and matrix metalloproteases that affect both neoplastic 
and non-neoplastic cells within the tumor microenvironment (Kalluri and Zeisberg 2006).  
For example, cancer-associated fibroblasts known as myofibroblasts secrete stromal cell-
derived factor 1 (SDF1) resulting in recruitment of endothelial cells and direct 
stimulation of breast cancer cell proliferation (Orimo et al. 2005).  Additionally, cancer 
cell invasiveness is altered in response to different extracellular matrix components 
produced by fibroblasts, such as collagen (Öhlund et al. 2013).  Another key aspect of 
growing tumors is recruitment of blood vessels composed of endothelial cells and 
pericytes to provide the tumor with oxygen and nutrients as well as the removal of 
potentially harmful metabolic byproducts.  Additionally, blood (and lymphatic) vessels 
provide tumors with routes to metastasize to distal locations.  The initiation of tumor 
angiogenesis, also known as the “angiogenic switch,” may occur at any tumor stage and 
is characterized by aberrant vascular structure (Bergers and Benjamin 2003).  Unlike 
normal blood vessels, tumor blood vessels are disorganized, irregularly shaped, and can 
have dead ends resulting in vascular leakage and a relatively hypoxic tumor 
microenvironment.  Targeting tumor vasculature, for example by pharmacological 
inhibition of vascular endothelial growth factor receptor (VEGFR) (Batchelor et al. 2007) 
or antibody-based blockade of VEGF (Burger et al. 2011), may impact tumor progression 
and sequelae, such as swelling that may impinge on neighboring organs.   
Understanding the tumor microenvironment is an active and diverse field of 
interest resulting in the much needed development of novel therapies.  However, perhaps 
the most exciting and clinically relevant hallmark of the tumor microenvironment is the 
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interaction between tumors and the immune system, as evidenced by Cancer 
Immunotherapy being named Science’s “Breakthrough of the Year” in 2013.   
 
Tumors and the immune system 
Tumor-infiltrating leukocytes spontaneously recruited by tumors comprise the 
most heterogeneous population of cells within the tumor-microenvironment.  Tumor- and 
normal neighboring cell-derived signals incited by growing tumors, such as damage 
associated molecular patterns (DAMPs), initially recruit innate immune cells, such as 
dendritic cells (DCs).  Upon activation, DCs transit to lymphoid organs where they prime 
adaptive immune cells, such as T cells, to respond to the tumor.  Both lymphocytic and 
myeloid cells are found within tumors and can have pro- or anti-tumor functions.  
According to the “immunoediting hypothesis,” the interaction between the immune 
system and tumors can progress through three stages: Elimination, Equilibrium, and 
Escape (Dunn, Old, and Schreiber 2004; Mittal et al. 2014).  Tumors may initiate at and 
transition between any of these stages.  During the “Elimination” stage, tumors 
recognized by the immune system trigger a cytotoxic response that eradicates the tumor.  
Evidence for the elimination stage was demonstrated in mice that spontaneously develop 
B cell leukemias via tissue-specific overexpression of c-myc.  In immunocompetent mice, 
these leukemic cells are eliminated by approximately 6 weeks of age; however, mice 
subjected to NK and T cell depletion fail to reject these spontaneous early cancer cells 
(Croxford et al. 2013).  If early tumors are not eliminated by the immune system, they 
may graduate to the “Equilibrium” stage where, despite immune pressure, undetected 
tumors are not rejected.  Clinically, evidence of the equilibrium stage can be found in 
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immunosuppressed transplant patients who develop tumors in organs from 
immunocompetent donors that were grossly normal at time of harvest (MacKie, Reid, and 
Junor 2003).  Evidence of the equilibrium stage was experimentally demonstrated using a 
mouse model where previously undetected carcinogen-induced sarcomas were only able 
to grow out when the mice were subjected to CD4, CD8, and Interferon-γ (IFN-γ) 
depletion (Teng et al. 2012).  Presumably, neoplastic cells were present but unable to 
form palpable tumors in these mice prior to depletion, which would suggest that the 
tumors were indeed in the equilibrium stage.  If the immune system is incapable of 
complete eradication, then tumors may proceed to the “Escape” stage of immunoediting.  
At this point, tumors are able to avoid immune destruction, allowing for progressive 
growth and clinical pathology.  Mechanisms of tumor escape include strategies to reduce 
immune recognition as well as tumor-driven immunosuppression.  The relative 
importance of each of these mechanisms likely varies according to tumor type.  In highly 
mutated tumors, such as malignant melanomas and carcinogen-induced preclinical 
models, mutational neoantigens are targeted by the immune system (Gubin et al. 2015; 
Robbins et al. 2013).  In these tumors, loss of MHC (Angell et al. 2014) or loss of 
antigenic epitopes (Sotillo et al. 2015) may result in tumor escape.  Virtually all tumors 
that have successfully avoided immune destruction do so at least in part by creating an 
immunosuppressive microenvironment.  Cancer cell-intrinsic mechanisms of suppression 
include secretion of immunosuppressive cytokines, for example transforming growth 
factor beta (TGF-β) (Stephen et al. 2014), and cancer cell surface expression of inhibitory 
ligands, such as PD-L1 (Lyford-Pike et al. 2013).  Tumors also recruit suppressive 
leukocytes, such as tolerogenic dendritic cells (DCs) (Scarlett et al. 2012), myeloid-
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derived suppressor cells (MDSCs) (Youn et al. 2008), and regulatory T cells (Tregs) 
(Serrels et al. 2015). 
Despite immune evasion being one of the hallmarks of growing cancers, evidence 
suggests that the immune system is still capable of exerting antitumor pressure.  For 
example, increased T cell infiltration is a positive prognostic indicator in a variety of 
tumors, indicating that the immune system is activated even in established tumors (L. 
Zhang et al. 2003; Hwang et al. 2012).  Additionally, the success of immune checkpoint 
inhibitory therapies, for example anti-PD1 and anti-CTLA-4, demonstrates that tumors 
spontaneously elicit protective immune reactions (Jensen et al. 2013; Akbay et al. 2013).   
Tumor immunoediting is a dynamic and complex process, which can proceed in a 
non-linear manner.  To better understand the interaction between tumors and the immune 
system, it is important to recognize that inflammation underlies the recruitment and 
behavior of leukocytes within the tumor microenvironment. 
 
Inflammation and cancer 
 Due to the continued presence of aberrant stromal cells such as myofibroblasts, 
neovascularization, and infiltrating leukocytes, tumors have been described as “wounds 
that never heal” (Dvorak 1986).  As is the case in wound healing, inflammation is a major 
characteristic of established tumors.  Inflammation broadly describes the milieu of 
cytokines and the cells they elicit within the tumor microenvironment that can have pro- 
or anti-tumor effects.  Acute inflammation results in the recruitment of antitumor 
cytotoxic innate and adaptive immune cells; however, if a tumor is not eradicated, 
chronic inflammation provides pro-tumor signals, such as the accumulation of 
8 
 
immunosuppressive leukocytes.  Many strategies have been employed to shift the balance 
between pro- and anti-tumor inflammation (Coussens, Zitvogel, and Palucka 2013; 
Cubillos-Ruiz et al. 2012; Scarlett et al. 2009).   
One of the major players in tumor-associated inflammation are myeloid cells, 
such as macrophages and dendritic cells (DCs).  Under normal physiological conditions, 
macrophages and DCs respond to pathogen- and damage-associated molecular patterns to 
present antigen and activate adaptive immune cells.  However, in numerous tumor 
models, tumors drive aberrant myelopoiesis, resulting in the accumulation of tumor-
promoting populations.  For example, in an autochthonous model of ovarian cancer, early 
stage DCs trigger a protective antitumor immune response dependent on CD8 T cells, 
while late stage DCs suppress antitumor immunity (Scarlett et al. 2012).  Tumor-
associated macrophages (TAMs) also appear to have both anti- and pro-tumor 
phenotypes, classified into the in vitro categories as either classical M1 or alternative M2 
macrophages (Chanmee et al. 2014).  M1 TAMs produce antitumor cytokines, such as 
IL-12, while M2 TAMs support tumor survival by producing pro-tumor cytokines, such 
as IL-10 and TGF-β, and expressing immunosuppressive enzymes, such as IDO and 
arginase (Woo, Corrales, and Gajewski 2015; Parsa et al. 2012).     
Similar to the dual potential of myeloid cells in tumor-associated inflammation, T 
cells are also capable of serving as anti- or pro-tumor effectors.  Th1 CD4 helper T cells 
produce IFN-γ, which helps trigger CD8 cytotoxic T cell activation and primes cancer 
cells for killing by up-regulating MHC-I (Angell et al. 2014).  However, IFN-γ also 
induces expression of PD-L1 providing tumors with the means to induce T cell 
exhaustion (Lee et al. 2006).  In addition to Th1, CD4 T cell polarization can result in 
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Th2 and regulatory T cells (Tregs), both of which accelerate malignant progression.  Th2 
cells produce cytokines, such as IL-4 that stimulate the differentiation of pro-tumor 
macrophages (Q. Zhang et al. 2015).  Tregs inhibit antitumor immune responses and are 
often associated with worse clinical outcomes (Curiel et al. 2004).  Tregs suppress 
conventional T cell proliferation and effector function through a number of direct and 
indirect mechanisms (Schmidt, Oberle, and Krammer 2012).  Tregs can directly suppress 
conventional T cells by producing suppressive cytokines and metabolites, such as IL-10, 
IL-35, TGFβ, and adenosine (Collison et al. 2010; Mandapathil et al. 2010).  Additionally 
and controversially, Tregs express high levels of the IL-2 receptor CD25, which removes 
IL-2 from the tumor microenvironment, thereby depriving conventional T cells of an 
important survival/proliferation signal (Pandiyan et al. 2007).  In addition, Tregs are 
capable of indirectly suppressing conventional T cells by expressing high levels of 
CTLA-4.  CTLA-4 has a higher affinity for costimulatory molecules, such as CD80 and 
CD86 expressed by antigen presenting cells compared to CD28.  This allows for Tregs to 
functionally reduce APC expression of CD80 and CD86, which impairs their ability to 
activate conventional T cells (Cederbom, Hall, and Ivars 2000).  Strategies to reduce 
tumor progression by preventing Treg accumulation, for example by inhibiting 
chemokine CCL5 tumor secretion (Serrels et al. 2015) and antibody depletion of CTLA-
4+ and OX40+ cells (Marabelle et al. 2013), demonstrate that Tregs can be potent 
immunosuppressive players in the tumor microenvironment. 
It is clear that the host inflammatory response to tumors is a major determinant of 
the composition and function of the tumor microenvironment.  Inflammation initially 
triggers antitumor immune responses; however, chronic inflammation can have the 
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opposite effect and suppress antitumor immunity.  Therefore, there is great interest in 
further understanding factors that influence the host “macroenvironment.”   
Endocrine signals are thought to impact inflammation, but have largely remained 
unexplored in the context of the tumor microenvironment.  In particular, estrogens are 
known for their immunomodulatory effects and are thought to contribute to sex 
differences in inflammation and autoimmune disease (Oertelt-Prigione 2012a; Oertelt-
Prigione 2012b; Hughes and Choubey 2014).  However, the primary interest in estrogens 
with regard to cancer has focused on their neoplastic cell-intrinsic effects, such as their 
ability to simulate estrogen receptor positive (ER+) breast cancer proliferation.  To treat 
such cancers, estrogen antagonists have been developed and are commonly used in the 
clinic.  Therefore, understanding the potential impact of estrogens on the tumor 
microenvironment is a novel concept, which has immediate therapeutic potential in a 
variety of tumors, including non-breast and ER negative cancers. 
 
Estrogens and their receptors 
Estrogens (estrone, E1; estradiol, E2; and estriol, E3) are steroid hormones 
produced by the aromatization of androgens, which are metabolized from cholesterol 
(Gruber et al. 2002).  In premenopausal women, the most potent estrogen, E2, is 
produced mainly by the ovaries.  Despite being present at lower concentrations, estrogens 
are also produced and have important biological functions in males and postmenopausal 
women.  Notably, adipose tissue expresses aromatase thus making it a site for peripheral 
estrogen conversion.  Individuals with large amounts of adipose tissue tend to have 
higher levels of estrogens (Iyengar, Hudis, and Dannenberg 2015; Mauras et al. 2015), 
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which has been hypothesized to predispose them to certain estrogen-related diseases.  For 
example, obese individuals are at a higher risk of breast and endometrial cancers and 
metabolic syndrome (Matic et al. 2013).  Additionally, estrogen signaling can be 
provided by environmental exposure to xenoestrogens, such as phytoestrogens present in 
soy-based diets or endocrine-disrupting chemicals like bisphenol A, which is present in 
plastic products (Katchy et al. 2014).  In addition, estrogens can be further metabolized 
into 2-hydroxyestrogens, 16α-hydroxyestrogens, and methoxylated estrogens, which are 
also biologically active (Stubelius et al. 2014; Li et al. 2014).  In vitro, estrogens are 
ubiquitously found in typical cell culture media containing fetal bovine serum and phenol 
red, which is estrogenic (Furuya et al. 1989; Berthois, Katzenellenbogen, and 
Katzenellenbogen 1986). 
 Estrogens signal through G protein-coupled estrogen receptor 1 (GPER) and, 
predominantly, the nuclear receptors, estrogen receptor α (ERα) and β (ERβ).  GPER 
activation by ligand binding results in rapid non-genomic signaling, similar to other G 
protein-coupled receptors.  ERα and β are comprised of an N-terminal domain containing 
an activation function domain (AF1), a highly conserved DNA binding domain, and a 
ligand binding domain, which contains a second activation function domain (AF2) 
(Kumar et al. 2011).  Upon ligand binding, ERs translocate into the nucleus where they 
dimerize and bind estrogen response elements (EREs; 5’-GGTCAnnnTGACC-3’), thus 
mediating transcription via AF1 and AF2 domain interaction with coactivators, 
corepressors, and general transcriptional machinery.  Importantly, AF1 is capable of 
transcriptional activation independent of ligand binding.  On the other hand, AF2 activity 
requires ligand binding (Arnal et al. 2013).  Therefore, in addition to classical ER-E2 
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binding and activation, ERs are also capable of ligand-independent transactivation by 
binding to other transcription factors, such as X box-binding protein 1 (XBP-1) (Ding et 
al. 2003).  Additionally, ERs are capable of forming complexes with other transcription 
factors, such as AP-1, SP1, and NF-κB.  The DNA binding domains of these transcription 
factors tether ERs to DNA resulting in estrogen regulation of genes that lack promoter 
EREs (Candelaria, Liu, and Lin 2013).   
 Expression of estrogen receptors is pervasive, dynamic, and varies by receptor.  
According to the Human Protein Atlas (www.proteinatlas.org), ERα is expressed most 
prominently by the female reproductive system (cervical, vaginal, endometrial, fallopian 
tube, breast, and ovarian tissue) and at lower levels in other tissues; ERβ expression is 
more varied, but highest in testis, ovary, and adrenal gland; and GPER is expressed in 
nearly all tissues (Uhlén et al. 2015).  Notably, ERα, ERβ, and GPER are expressed by 
lymphoid and myeloid leukocytes (Yakimchuk, Jondal, and Okret 2013; Brunsing, 
Owens, and Prossnitz 2013).  ER expression is dynamic and can be regulated by the 
menstrual cycle (Slayden and Brenner 2004) or by other factors.  For example, ERα is 
up-regulated by male and female macrophages upon lipopolysaccharide (LPS) activation; 
however, this increase is significantly more pronounced in females compared to males 
(Campesi et al. 2016).  Additionally, the ratio of ERα to ERβ expression appears to 
decrease in cells found in inflammatory and hypoxic settings (Straub 2007). 
 Estrogens are a diverse class of molecules with the potential to affect a wide 
variety of target cells and biological systems through the near ubiquitous expression of 
ERα, ERβ, and GPER. 
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Physiological roles of estrogens 
 Estrogens underlie a number of important physiological processes (Gruber et al. 
2002).  Predominantly, estrogens are known for their role in reproduction.  Estrogen 
signaling is required for normal sexual development, as female mice lacking ERα are 
completely infertile, and the fertility of male ERα knockout mice is greatly reduced 
(Lubahn et al. 1993).  Female ERβ KO mice show similar, albeit less severe, defects in 
fertility (Walker and Korach 2004).  Female mice that lack both ERα and ERβ appear to 
undergo partial sex reversal resulting in the formation of ovarian follicles that resemble 
seminiferous tubules of testis (Couse et al. 1999).   
The diverse biological effects of estrogens are illustrated well in premenopausal 
women, in whom estrogen levels vary according to the menstrual cycle.  During the 
follicular phase, the pituitary secretes increasing concentrations of follicle-stimulating 
hormone (FSH) to stimulate the development of several follicles, one of which continues 
to develop and produce E2.  Estrogen levels produced by follicular granulosa and theca 
cells continue to increase and peak in the preovulatory phase.  This increase stimulates 
endometrial cell proliferation, resulting in uterine wall thickening, and, upon reaching a 
certain threshold, triggers a pituitary surge in luteinizing hormone, which in turn initiates 
ovulation.  During the ovulatory phase, the follicle releases its egg, forms the corpus 
luteum, and E2 levels decrease.  In the subsequent luteal phase, the corpus luteum 
produces progesterone and resumes E2 production.  E2, now in combination with 
progesterone, continues to induce uterine wall thickening.  If fertilization does not occur, 
increasing amounts of estrogen and progesterone suppress FSH and LH, resulting in 
atrophy of the corpus luteum.  Without the corpus luteum, estrogen and progesterone 
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levels drop resulting in shedding of the endometrial lining, and the menstrual cycle 
restarts.  If fertilization does occur, the developing blastocyst produces human chorionic 
gonadotropin (hCG), which sustains the corpus luteum and estrogen production.  During 
pregnancy, the placenta and fetus produce large amounts of estrogen, which supports 
fetal development and prepares the mother for breastfeeding by stimulating proliferation 
of ductal epithelial cells. 
In addition to reproduction, estrogens play a prominent role in other physiological 
systems, such as bone metabolism, wound healing, and angiogenesis.  In bone 
metabolism, osteoporosis is caused by estrogen deficiency, which can occur during 
menopause and be treated with estrogen replacement therapy (Gruber et al. 2002).  
Estrogens control the balance between osteoblasts, responsible for bone formation, and 
osteoclasts, responsible for bone resorption.  In estrogen-deficient ovariectomized mice, 
bone remodeling skews in favor of osteoclasts through several mechanisms in which T 
cell and osteoblast cytokine production are altered, resulting in increased osteoclast 
differentiation (Pacifici 2008).  In cutaneous wound healing, estrogens appear to have a 
protective effect, as estrogen treatment increases wound healing in postmenopausal 
women and ovariectomized mice (Mukai et al. 2014).  Additionally, studies using a 
knockout mouse model demonstrate that cell-intrinsic ERα signaling is required for 
macrophages to acquire a pro-healing phenotype (Campbell et al. 2014).  Additionally, 
myofibroblasts, which promote wound healing, express and are regulated by ERα (Yeh et 
al. 2016).  In angiogenesis, estrogen promotes the mobilization of bone marrow-derived 
endothelial cells, resulting in neovascularization.  This process requires up-regulation of 
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hypoxia-induced factor 1α (HIF-1α) in epithelial cells resulting in VEGF production 
(George et al. 2012).   
Estrogens perform a number of important biological processes, such as 
reproductive development, bone metabolism, wound healing, and angiogenesis.  It is 
important to note that these processes are often co-opted by tumors.  ER+ breast tumors 
proliferate in response to E2.  Bone metabolism affects the microenvironment of bone 
metastasis and potentially impacts the host hematopoietic response to the tumor (Inoue et 
al. 2007; Sceneay, Smyth, and Möller 2013).  Macrophages, fibroblasts, and endothelial 
cells, crucial for wound healing and angiogenesis, are also found in the tumor 
microenvironment.  As discussed previously, inflammation underlies much of the host 
response to tumors, such as antitumor immunity.  In addition to the above mentioned 
systems, estrogen has potent inflammatory effects, thus implicating estrogen as a key 
mediator of the tumor microenvironment. 
 
Estrogen and inflammation 
 Estrogens affect the differentiation and function of a wide variety of leukocytes, 
ultimately resulting in pro- and anti-inflammatory effects (Table 1.1).  The dual nature of 
estrogens in inflammation is demonstrated by their effects on various inflammatory 
autoimmune diseases.  As an aside, autoimmune diseases are generally more prevalent in 
women compared to men, with estrogens thought to be a key factor underlying this 
sexual dimorphism (Pennell, Galligan, and Fish 2012; Khan and Ansar Ahmed 2015).  In 
systemic lupus erythematous (SLE), which is considered to be a Th2-driven autoimmune 
disease due to the presence of auto-antibodies, estrogens appear to be an exacerbating 
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factor (Jiang et al. 2007).  High levels of estrogen, such as those achieved in pregnancy, 
can trigger SLE flare-ups by increasing Th2 CD4 helper T cell polarization.  Th2 cells 
support B cells, which produce pathogenic auto-antibodies (Doria et al. 2006).  On the 
other hand, multiple sclerosis and rheumatoid arthritis, which are considered to be a 
Th1/17-driven diseases are ameliorated by increased ERα-driven suppression of Th1 and 
Th17 CD4 polarization (Lélu et al. 2011). 
 Similar to autoimmunity and reminiscent of tumors, pregnancy is considered an 
inflammatory state due to the presence of non-self, fetal antigens.  High estrogens levels, 
in addition to supporting fetal development, are believed to be important in maintaining 
feto-maternal tolerance.  During pregnancy, estrogens skew CD4 helper T cell 
polarization from a Th1 towards a Th2 phenotype (Robinson and Klein 2012).  
Additionally, pregnancy levels of E2 favor CD4 Treg differentiation, which may be 
important in suppressing maternal immune responses against the fetus (Haghmorad et al. 
2014). 
The specific effect of E2 on immune cell subsets is further complicated by its 
dependence on a combination of additional cytokine signals.  Therefore, depending on 
additional cytokines, E2 may have very different effects on the same cells.  For example, 
myeloid progenitor cells treated with GM-CSF or Flt3 ligand differentiate into dendritic 
cells.  Combining GM-CSF treatment with E2 increases DC differentiation; however, 
combining Flt3 ligand treatment with E2 actually decreases the yield of DCs (Carreras et 
al. 2008). 
 Estrogens influence the response of leukocytes to inflammatory signals, which 
can either increase or dampen ongoing inflammation.  Therefore, estrogen levels are 
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potentially an important factor to consider when determining immune responses induced 
by tumor-driven inflammation. 
 
Estrogen and the tumor microenvironment 
 The prevalence of certain cancers varies according to sex, which suggests that 
differences in sex hormones, such as estrogens, may play a role in tumorigenesis.  For 
example, hepatocellular carcinoma is more prevalent in men as well as in a carcinogen-
induced mouse model.  Here, liver macrophages were found to respond to carcinogen-
induced injury by releasing IL-6, which increases tumorigenesis.  In females, estrogen 
suppresses IL-6 release resulting in lower rates of hepatocellular carcinoma (Naugler et 
al. 2007). 
 In addition to tumorigenesis, estrogens are capable of contributing to tumor 
progression independent of cancer cell-intrinsic effects.  E2 treatment of 
immunocompromised mice bearing patient-derived ER- xenografts resulted in ERα-
dependent, cell-intrinsic mobilization of macrophages, which was associated with 
increased vascularization (Iyer et al. 2012). 
  
Estrogen and MDSCs 
 Myeloid-derived suppressor cells (MDSCs) are potent tumor-promoting cells.  
MDSCs originate from bone marrow in response to chronic inflammatory cytokines, such 
as granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-6 (Marigo et al. 
2010).  MDSCs are truly pathological cells that do not differentiate under normal 
physiological conditions.  Instead, they differentiate in response to tumor-associated 
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inflammation via a mechanism requiring the loss of retinoblastoma protein (Rb1) (Youn 
et al. 2013).  In addition to suppressing immune responses (Condamine et al. 2014), these 
cells are capable of supporting tumor progression by regulating tumor cell division, 
invasion, and vasculogenesis (Talmadge and Gabrilovich 2013). 
There is now emerging evidence linking estrogen to MDSCs in chronic 
inflammatory states.  Notably, pregnancy, where estrogen levels are the highest, is 
associated with increased numbers of MDSCs (Köstlin et al. 2014), which may help 
suppress maternal rejection of the fetus (Pan et al. 2016).  Additionally, in pregnancy, 
hosts are more susceptible to tumor metastasis, which may be the result of increased 
MDSC accumulation in metastatic tissue (Mauti et al. 2011).  Estrogens also appear to be 
associated with increased MDSCs in the peripheral blood of lupus patients as wells as in 
mice treated with TNF-α suggesting that estrogens increase MDSC accumulation in 
individuals with chronic inflammation (Dong et al. 2015). 
Despite estrogens and MDSCs being common mediators of inflammation in a 
variety of pathological settings and compelling evidence linking the two, currently there 
have been no studies expressly demonstrating that in tumors, estrogens influence the 
accumulation of MDSCs, which ultimately impacts tumor progression. 
 
Hypothesis 
 I hypothesize that estrogens, in combination with tumor-associated inflammation, 
directly and indirectly suppress antitumor T cell responses by skewing CD4 T cell 
differentiation and by increasing MDSC accumulation (Figure 1.2). 
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Figures 
Figure 1.1 
 
Figure 1.1: Hallmarks of cancer 
Tumors are a combination of immortalized neoplastic cells that continue to proliferate 
regardless of environmental cues and normal cells recruited in response to the tumor.  
The host’s systemic response to developing tumors is complex with pro- and anti-tumor 
effects.  Adapted from Hanahan and Weinberg (2011).  
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Table 1.1 
 
 B cells T cells Macrophages 
/ DCs 
NK Cells Fibroblasts 
High 
(Pregnancy) 
> 7000 ng/mL 
↑ Antibodies ↓ TNF 
↑ IL-4 
↑ IFN-γ 
↑ IL-10 
↑ TGFβ 
↓ TNF 
↓ IL-6 
↓ IL-1β 
↑ IL-10 
 
↓ Activity ↓ MMP-1/3 
↓ MCP-1 
↑ IL-6 
↑ bFGF 
↑ TIMP 
↑ OPG 
Low 
(Menopause) 
< 10 pg/mL 
↑ Antibodies ↑ TNF 
↑ IFN-γ 
↑ IL-1β ↑ Activity  
 
 
Table 1.1: Pro- and anti-inflammatory effects of estradiol  
 
Depending on concentration and cell type, estradiol (E2) can result in the secretion of 
pro- or anti-inflammatory cytokines (Straub 2007). 
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Figure 1.2 
 
 
Figure 1.2: Hypothesis for the effects of E2 on the ovarian tumor microenvironment 
 
Estrogens, which may originate from endogenous or external sources, augment the 
response of BM to tumor-initiated inflammation (i.e., cytokines).  This results in 
increased mobilization of MDSCs that impair antitumor immune responses, further 
accelerating malignant progression. 
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CHAPTER 2 
 
 
 
MATERIALS AND METHODS 
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Mice 
Female 5-8 week old wild type (WT) C57BL/6 and congenic Ly5.1 mice were 
purchased from the Charles River Frederick facility.  Rag1 knockout and Esr1 knockout 
(ERα KO) were originally purchased from The Jackson Laboratory and bred in-house.  
ERα genotyping was performed by digesting tail clippings and PCR (Table 2.1).  All 
mice were maintained in pathogen-free barrier facilities and fed ad libitum a diet 
containing soy bean meal (Pico-vac Lab Mouse Diet 20, LabDiet).  All experiments were 
conducted with the approval of the Wistar Institute Institutional Animal Care and Use 
Committee. 
 
In vivo Estrogen Depletion 
Estrogen depletion was achieved by ovariectomization (OVX) performed at 5 
weeks of age.  Mice were prepared for surgery by anesthetization via i.p. injection of a 
mix of ketamine (80-100 mg/kg) and xylazine (8-10 mg/kg) in sterile saline, shaving, and 
the skin sterilization using betadine and ethanol.  Meloxicam (1 mg/kg) and Buprenex (2 
mg/kg) were injected s.q. for pain management.  Small incisions were then made in the 
peritoneal wall allowing exteriorization of ovaries.  Fallopian tubes were ligated shut 
approximately 3 mm proximal to ovaries prior to ovarian excision.  Following removal of 
ovaries, the remaining fallopian tubes were returned to the peritoneal cavity, and 
peritoneal wall incisions were sutured shut.  Mice were given additional doses of 
Meloxicam and Buprenex for pain management and allowed to recover for two weeks. 
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In vivo Estrogen Augmentation 
For estrogen augmentation, mice were treated with vehicle (0.1% ethanol) or 10 
μM estradiol (USP grade, Sigma) drinking water refreshed every 3-4 days in light-
protective amber bottles.   
 
Cell Lines 
The mouse ovarian epithelial cell line, ID8, was provided by K. Roby 
(Department of Anatomy and Cell Biology, University of Kansas) (Roby et al. 2000) and 
retrovirally transduced to express Defb29 and Vegf-a (Conejo-Garcia et al. 2004).  MCF-
7, MDA-MB-231, LLC1, and B16.F10 cells were obtained from American Type Culture 
Collection.   
 
In vivo Tumor Challenge 
Peritoneal tumors were initiated in mice by injecting 3X106 ID8-Defb29/Vegf-a 
cells intraperitoneal (i.p.).  Intraperitoneal cells were harvested from tumor-bearing mice 
by flushing the peritoneal cavity with PBS.  Cells were maintained in vitro at 37° C, 5% 
CO2 by culturing in RPMI+10% FBS or steroid free media (SFR10), which was 
comprised of phenol red-free RPMI+10% charcoal-stripped FBS (Gibco).   
 
In vitro Estrogen Treatment 
Cells were treated in vitro with vehicle (0.1% DMSO) or varying concentrations 
of estradiol, fulvestrant, or Methylpiperidino pyrazole (MPP) purchased from Cayman 
Chemical.  Cell line proliferation was determined by MTS assay (Promega), and 
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increased/decreased proliferation relative to vehicle was calculated from absorbance 
readings at 490 nm at 30 minutes.  For E2-induced proliferation experiments using 
SFR10, cells were incubated in SFR10 2 days prior to 5-day treatment. 
 
Mixed BM Chimeras 
 To generate mixed BM chimeras, nucleated BM cells were collected from adult 
age-matched CD45.1 (congenic) WT or CD45.2 Esr1-/- donor mice.  Mice were 
reconstituted with 1-5X106 total cells containing a 1:1 mix of WT and KO cells via retro-
orbital injection into adult recipients approximately 5 hours after receiving a lethal dose 
(~1100 rad) of γ-radiation.  Mixed chimeras were analyzed after 6-8 weeks as indicated. 
 
Human Samples 
Human ovarian carcinoma tissues were procured under a protocol approved by 
the Committee for the Protection of Human Subjects at Dartmouth-Hitchcock Medical 
Center (#17702) and under a protocol approved by the Institutional Review Board at 
Christiana Care Health System (#32214) and the Institutional Review Board of the Wistar 
Institute (#21212263).  Bone marrow (BM) was obtained from Stage I-II lung cancer 
patients scheduled for surgical resection at the Hospital of the University of Pennsylvania 
and The Philadelphia Veterans Affairs Medical with approval from respective 
Institutional Review Boards.  All patients selected for entry into the study met the 
following criteria: (i) histologically confirmed pulmonary squamous cell carcinoma 
(SCC) or adenocarcinoma (AC), (ii) no prior chemotherapy or radiation therapy within 
two years, and (iii) no other active malignancy.  BM cell suspension was obtained from 
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rib fragments that were removed from patients as part of their lung cancer surgery.  
Informed consent was obtained from all subjects. 
 
Immunohistochemistry 
 Frozen ovarian tissue sections were thawed and allowed to dry overnight before 
being fixed with chilled acetone for 10 minutes.  After washing with PBS, endogenous 
peroxidases were quenched by adding 0.3% H2O2 for 10 minutes at room temperature.  
Following a second wash, the slides were then blocked using 500 µg/mL human γ-
globulin in PBS for 30 minutes at room temperature.  Slides were then stained for ERα 
using mouse anti-ERα primary antibody 6F11 (Table 2.2) diluted 1:100 in PBS and 
incubated for 1 hour at room temperature.  Following another PBS wash, slides were 
incubated for 30 minutes at room temperature with 7.5 µg/mL biotinylated anti-mouse 
IgG secondary antibody diluted in PBS+3% goat serum.  To develop, ABC complex 
(Vector Laboratories) was added to the samples, incubated for 30 minutes at room 
temperature, washed, and then treated with colorigenic DAB substrate.  Subsequently, 
nuclei were counterstained using hematoxylin.  Following dehydration, slides were 
mounted using Permount and visualized via bright field microscopy (Nikon E600 Upright 
Microscope). 
 
Flow Cytometry  
Flow cytometry was performed by staining mouse cells with Zombie Yellow 
viability dye (Biolegend #423103), blocking with anti-CD16/32 (2.4G2 cell supernatant), 
and staining for 30 min at 4° C with fluorochrome-conjugated anti-mouse antibodies 
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purchased from Biolegend or Tonbo Biosciences (Table 2.2).  Similarly, human samples 
were stained with Zombie Yellow, blocked with 0.5% FBS + 3 mg/mL human gamma 
globulin, and stained for 30 min at 4° C with fluorochrome-conjected anti-human 
antibodies (Table 2.2).  Samples were subsequently sorted using a FACSAria II or run 
using an LSRII and analyzed using FlowJo.   
 
ELISpot  
Dendritic cells (BMDCs) were differentiated by culturing WT mouse bone 
marrow for 7 days with 20 ng/mL GM-CSF (Peprotech 315-03), refreshed every 3 days.   
BMDCs were subsequently primed with tumor antigen by pulsing for 24 hours with 
irradiated (100 Gy+30 minutes UV) ID8-Defb29/Vegf-a cells at a ratio of 10 BMDCs to 1 
tumor cell.  ELISpot assay was performed by stimulating 1X105 T cells FACS-isolated 
from peritoneal wash with 1X104 antigen-primed BMDCs in a 96-well filter plate 
(Millipore MSIPS4510) coated with IFN-γ capture antibody according to manufacturer’s 
guidelines (eBioscience 88-3784-88).  Following incubation at 37° C, 5% CO2 for 48 
hours, wells were treated overnight at 4° C with biotinylated IFN-γ detection antibody 
followed by 2 hour room temperature incubation with Avidin-AP (R&D Systems 
SEL002).  Positive spots were then developed using BCIP-NBT substrate (R&D Systems 
SEL002). 
 
Adoptive T Cell Transfer 
Naïve T cells were harvested from spleens of WT or ERα KO mice via RBC lysis 
followed by negative selection of B220+, CD16/32+, CD11b+ and MHC-II+ cells using 
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anti-rat IgG magnetic beads (Thermo 11035) conjugated to rat IgG antibodies derived 
from bioreactor hybridoma cultures (Table 2.2).  T cells were then primed for 5 days 
with BMDCs pulsed with irradiated tumor cells (see above) and supplemented with 10 
U/mL IL-2 + 1 ng/mL IL-7 (Peprotech), as reported (Y. C. Nesbeth et al. 2010).  A total 
of 1X106 primed T cells per mouse was injected i.p. at 7 and 14 days post tumor 
injection. 
 
Bone Marrow-Derived MDSC Cultures 
Mouse MDSCs were expanded from WT mouse bone marrow harvested by 
flushing tibias and femurs with media.  Following red blood cell lysis, 2.5X106 cells were 
cultured in 10 mL of RPMI+10% FBS augmented with recombinant mouse 40 ng/mL 
GM-CSF+40 ng/mL IL-6 (Peprotech) and incubated at 37°C, 5% CO2 3 or 6 days.  
Vehicle, estradiol, or methylpiperidino pyrazole (MPP) treatments were added as 
described above.  For 6 day cultures, cytokines and estrogen treatments were refreshed on 
day 3.  Following incubation, floating and adherent cells were collected, and M-MDSCs 
and G-MDSCs were isolated via Miltenyi MDSC purification kit (Miltenyi 130-094-538) 
according to manufacturer’s protocol for further analysis.  Human MDSCs were 
expanded from human lung cancer patient bone marrow acquired as single cell 
suspensions (see above).  Briefly, 2X106 cells were cultured in 3 mL of IMDM+15% 
FBS supplemented with recombinant human 40 ng/mL GM-CSF+40 ng/mL IL6 
(Peprotech) and treated with Vehicle, 2µM, or 10µM MPP (see above) for 4 days.  Cells 
were subsequently harvested and analyzed by flow cytometry. 
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MDSC Suppression Assay 
Naïve WT T cells were purified from spleens as described above and labeled with 
the proliferation tracker CellTrace Violet according to manufacturer protocol (Molecular 
Probes).  T cell proliferation was stimulated by adding anti-CD3/CD28 mouse T-activator 
beads (Thermo) at a 1:1 T cell to bead ratio according to manufacturer protocol.  T cells 
(2X105) were subsequently co-cultured with MDSC at 1:4, 1:8, or 1:16 MDSC to T cell 
ratios in 200 µL R10 (containing 2-ME) and incubated for 3 days prior to flow cytometric 
analysis. 
 
Western Blot 
Cells were lysed in RIPA buffer (Thermo 89900) supplemented with a cocktail of 
protease inhibitors and phosphatase inhibitors (Thermo 78446), and Na3VO4 according to 
manufacturer protocol.  Protein quantification was determined via BCA assay, and 5-20 
µg protein was run on TGX 4-15% gradient gels (Bio-Rad 4561083).  Following transfer, 
polyvinylidene fluoride (PVDF) membranes were blocked with 5% bovine serum 
albumin in TBS+0.05% Tween-20.  Primary antibodies were added to membranes and 
incubated overnight with gentle agitation.  Following secondary staining with HRP-
conjugated anti-mouse or rabbit IgG, membranes were developed using ECL prime (GE 
Healthcare). 
 
Quantitative Real Time PCR 
Cells were lysed in Trizol buffer and RNA was subsequently purified using the 
RNEasy Plus Kit (QIAGEN).  Reverse transcription was carried out using the High-
30 
 
Capacity Reverse Transcription Kit (Applied Biosystems).  The resulting cDNA was then 
used for real time PCR using Power SYBR Green (Applied Biosystems) and 500 nM 
primers (Table 2.1).  ABI 7500 Fast Sequence Detection Software (Applied Biosystems) 
was used to quantify gene expression.   
 
Statistics 
 Significant differences in survival between experimental groups were determined 
by Kaplan-Meier Log-rank testing with a p-value < 0.05 deemed significant.  To 
determine whether the means of two groups (e.g., tumor volumes) differed significantly, 
both groups were first tested for Gaussian distribution using the Kolmogorov-Smirnov 
test.  If both populations were found to be normal, then unpaired two-tailed T-tests were 
used to calculate a p-value.  If at least one population was determined to not be normal, 
then Mann-Whitney tests were used.  As before, a p-value < 0.05 was deemed significant.  
All calculations were performed using GraphPad Prism. 
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Tables 
Table 2.1 
Application Target Primer Sequences 
Genotyping ERα WT allele (mouse) 5’-GGGGAGCCAGTCTGTAACTC-3’ 
5’-CTAGGCGACACGCTGTTGAG-3’ 
 ERα KO allele (mouse) 5’-TTCCACATACACTTCATTCTC A-3’ 
5’-ACTGGCCTCAAACACCTG-3’ 
qPCR Esr1 (human) 5’- CCACTCAACAGCGTGTCTC-3’ 
5’- GGCAGATTCCATAGCCATAC-3’ 
 Gapdh (mouse/human) 5’- CCTGCACCACCAACTGCTTA-3’ 
5’- AGTGATGGCATGGACTGTGGT-3’ 
 Stat3 (mouse) 5’- GGGTCTGAAGTTGAGATTCTGCT-
3’ 
5’-GACTGATGAAGAGCTGGCTGACT-
3’ 
 Tbp (mouse) 5’- CACCCCCTTGTACCCTTCAC-3’ 
5’- CAGTTGTCCGTGGCTCTCTT-3’ 
 Jak2 (mouse) 5’- GTGTCGCCGGCCAATGTTC-3’ 
5’- CACAGGCGTAATACCACAAGC-3’ 
 
Table 2.1: Primers used 
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Table 2.2 
Application Target Clone Vendor 
Flow Cytometry CD45 (mouse) 30-F11 Tonbo 
 CD45.1 (mouse) A20 Biolegend 
 CD45.2 (mouse) 104 Biolegend 
 CD4 (mouse) GK1.5 Tonbo 
 CD8b (mouse) YTS156.7.7 Biolegend 
 CD11b (mouse) M1/70 Biolegend 
 MHC-II (I-A/I-E) (mouse) M5/114.15.2 Biolegend 
 CD11c (mouse) N418 Tonbo 
 Ly6G (mouse) 1A8 Biolegend 
 Ly6C (mouse) HK1.4 Biolegend 
 Gr-1 (mouse) RB6-8C5 Biolegend 
 CD126 (mouse) D7715A7 Biolegend 
 CD130 (mouse) KGP130 Biolegend 
 CD44 (mouse) IM7 Tonbo 
 CD69 (mouse) H1.2F3 Biolegend 
 CD45 (human) HI30 Tonbo 
 CD11b (human) ICRF44 Biolegend 
 CD33 (human) WM53 Biolegend 
 HLA-DR (human) L243 Biolegend 
 CD14 (human) HCD14 Biolegend 
 CD15 (human) HI98 Bio 
T cell Isolation CD11b (mouse) M1/70 BioXcell 
 MHC-II (mouse) M5/114 n/a 
 B220 (mouse) RA3 n/a 
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 CD16/32 (mouse) 2.4G2 n/a 
Western Blot Stat3 124H6 Cell Signaling 
 Phospho-Stat3 (Tyr705) D3A7 Cell Signaling 
 Jak2 D2E12 Cell Signaling 
 ERα TE111.5D11 Thermo 
 Β-Actin AC-15 Sigma 
Immunohistochemistry ERα (human) 6F11 Thermo 
In vivo MDSC depletion Gr-1 RB6-8C5 Bio X Cell 
 Irrelevant IgG LTF-2 Bio X Cell 
  
Table 2.2: Antibodies used 
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CHAPTER 3 
 
 
 
ESTROGENS SUPPRESS ANTITUMOR IMMUNITY BY INCREASING 
THE ACCUMULATION OF MYELOID-DERIVED SUPPRESSOR CELLS 
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Abstract 
The role of estrogens in antitumor immunity remains poorly understood.  Here we 
show that estrogen signaling accelerates the progression of different estrogen insensitive 
tumor models by contributing to deregulated myelopoiesis.  Estrogens drive the 
mobilization of Myeloid-derived Suppressor Cells (MDSCs) and enhance their intrinsic 
immunosuppressive activity.  Differences in tumor growth were dependent on blunted 
antitumor immunity and, correspondingly, disappeared in immunodeficient hosts.  
Mechanistically, estrogen receptor alpha augmented the JAK-STAT3 pathway in human 
and mouse bone marrow myeloid precursors by up-regulating JAK2 and, subsequently, 
enhancing IL-6-driven overexpression of total STAT3.  Therefore, estrogen signaling is a 
crucial mechanism underlying pathological myelopoiesis in cancer.  Our work suggests 
that new antiestrogen drugs that have no agonistic effects may have benefits in a wide 
range of cancers, independently of the expression of estrogen receptors in tumor cells, 
and may synergize with immunotherapies to significantly extend survival. 
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Introduction 
Estrogens are pleiotropic steroid hormones known to influence many biological 
processes that ultimately affect homeostasis, such as development and metabolism.   
Estrogens bind to two high-affinity receptors (ERα and β) that recognize estrogen 
response elements with different affinities and are differentially expressed in multiple 
tissues.  Due to their pathogenic role in accelerated malignant progression, ER+ breast 
cancers have been commonly treated with tamoxifen.  Tamoxifen, however, has mixed 
antagonist/agonist effect on Estrogen Receptors (ERs), depending on the cell type (Gallo 
and Kaufman 1997).  Correspondingly, alternative interventions are currently evolving as 
results from clinical testing emerge (Sini et al. 2016).  In contrast to breast cancer, 
antiestrogen therapies have proven to be effective in only some ovarian cancer patients 
(Hasan et al. 2005; del Carmen et al. 2003; Smyth et al. 2007; Argenta et al. 2009; 
Bowman et al. 2002).  However, these studies exclusively focused on ovarian cancer 
patients with ER+ tumors, which represent 31% for ERα and 60% for ERβ.  These studies 
therefore do not provide any insight into the effects of estrogen activity on non-tumor 
cells within the ovarian tumor microenvironment.  Additionally, ERβ may actually 
provide anti-proliferative signaling in ovarian cancer (Bossard et al. 2012). 
The tumor microenvironment plays a critical role in determining malignant 
progression as well as response to various therapies.  In particular, it is becoming evident 
that tumors elicit immune responses that ultimately impact survival.  In ovarian cancer, 
for instance, the presence of tumor-infiltrating lymphocytes is a major positive prognostic 
indicator of tumor survival (L. Zhang et al. 2003), and multiple T cell inhibitory 
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pathways have been identified (Stephen et al. 2014; Cubillos-Ruiz et al. 2009; Cubillos-
Ruiz et al. 2010).   
In addition to tumor cells, both ERs are expressed by most immune cell types, 
including T cells, B cells and NK cells, in which ERα46 is the predominant isoform 
(Pierdominici et al. 2010).  Correspondingly, estrogens influence helper CD4 T cell 
differentiation favoring humoral Th2 over cell-mediated Th1 responses (Salem 2004).   
Women have higher levels of estrogen than men, which may contribute to differences in 
the incidence of certain autoimmune diseases.  Most importantly, various cancers, such as 
colorectal, lymphoma, and hepatocellular cancer, exhibit sex biases that are at least partly 
explained by hormonal differences.  Obesity, which is associated with increased 
adipocyte production of estrogens, is also a risk factor for a number of cancers.  Changes 
in estrogen levels in women caused by menstruation, menopause, and pregnancy are 
associated with changes in the immune system, which could ultimately affect disease 
susceptibility.  For example, during the menstrual cycle the number of Tregs increases 
coinciding with increased estrogen levels during the follicular phase (Oertelt-Prigione 
2012a).  Importantly, women given hormone replacement therapy have a significantly 
increased risk of developing and dying from ovarian cancer (Beral et al. 2007).  Despite 
growing evidence implicating estrogen as a fundamental mediator of inflammation, 
currently little is known about its potential role in antitumor immune responses and the 
overall estrogen-responsive tumor microenvironment.   
Factors that characterize tumor-associated inflammation, such as IL-6, induce 
aberrant myelopoiesis in solid tumors, which fuels malignant progression in part by 
generating immunosuppressive myeloid cell populations (Gabrilovich, Ostrand-
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Rosenberg, and Bronte 2012).  In ovarian cancer, deregulated myelopoiesis results in the 
mobilization of Myeloid-Derived Suppressor Cells (MDSCs) from the bone marrow 
(Rutkowski et al. 2015) and, eventually, the accumulation of tumor-promoting 
inflammatory Dendritic Cells (DCs) with immunosuppressive activity in solid tumors 
(Scarlett et al. 2012; Tesone et al. 2016).  Additionally, canonical macrophages build up 
in tumor ascites (Scarlett et al. 2012; Huarte et al. 2008).  Although all of these cell types 
express at least ERα and are influenced by estrogen signaling (Kovats 2012; Kovats 
2015; Pan et al. 2016), the impact of estrogens on antitumor immunity remains elusive.  
Here, we show that estrogens, independently of the sensitivity of tumor cells to estrogen 
signaling, are a crucial mechanism underlying pathological myelopoiesis in ovarian 
cancer.  We report that estrogens drive MDSC mobilization and augment their 
immunosuppressive activity, which directly facilitates malignant progression.  Our data 
provide mechanistic insight into how the augmented estrogenic activity observed in 
BRCA1 mutation carriers (Widschwendter et al. 2013) may contribute to breast cancer 
progression.  Furthermore, this work provides a rationale for blocking estrogen signals to 
boost the effectiveness of anti-cancer immunotherapies. 
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Results 
Tumor cell-extrinsic estrogen signaling impairs protective immunity against ovarian 
cancer  
Nuclear expression of ERs specifically in neoplastic cells has been identified in 
human ovarian carcinomas of all histological subtypes, with strong signal in ~60% of 
high-grade serous tumors (Sieh et al. 2013).  ERα is the predominant estrogen receptor in 
at least mouse hematopoietic cells (Pierdominici et al. 2010).  To define the expression of 
ERα in human ovarian cancer-infiltrating leukocytes, we performed 
immunohistochemical analysis on 54 serous ovarian carcinomas.  Supporting previous 
reports, we found positive staining in tumor cells in ~35% of tumors (Figure 3.1A, left).  
In addition, we identified a second class of ovarian tumors in which ERα expression was 
confined to individual cells in the stroma (Figure 3.1A, right).  To confirm that 
hematopoietic cells at tumor beds indeed express ERα, we sorted (CD45+) cells from 7 
different dissociated human ovarian tumors.  As shown in Figure 3.1B, both tumor-
infiltrating (CD11b+) myeloid cells and (CD11b-) non-myeloid leukocytes express ERα.  
In addition, both myeloid and non-myeloid cells sorted from the bone marrow of a cancer 
patient were also ERα+, suggesting that in addition to potentially having tumor cell-
intrinsic effects, estrogens may also play wider a role in shaping the ovarian tumor 
immune-environment.  To determine the role of estrogen signaling in tumor-promoting 
inflammation or antitumor immunity, we used a preclinical model of aggressive ovarian 
cancer in which syngeneic epithelial ovarian tumor cells (ID8-Defb29/Vegf-a) develop 
intraperitoneal tumors and ascites that recapitulate the inflammatory microenvironment 
of metastasized human ovarian tumors (Stephen et al. 2014; Rutkowski et al. 2015; 
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Tesone et al. 2016; Conejo-Garcia et al. 2004).  Importantly, no ERα was detected in 
these cells, unlike tumor-associated myeloid cells (Figure 3.1C).  Most importantly, ID8-
Defb29/Vegf-a cells fail to respond to estradiol (E2) treatment or ER antagonism in vitro, 
unlike established estrogen-responsive MCF-7 cells (Figure 3.2).  Supporting a tumor 
cell-independent role of estrogen signaling in malignant progression, ovariectomized 
(OVX, estrogen-depleted) wild type mice survived significantly longer than non-OVX, 
aged-matched controls after orthotopic tumor challenge in multiple independent 
experiments (Figure 3.3A).  The effect of OVX is estrogen dependent, as OVX mice 
treated with E2 failed to survive as long as OVX mice treated with vehicle (Figure 
3.3A).  Most importantly however, the survival benefit imparted by ovariectomization 
disappeared in tumor-bearing immunodeficient RAG1 KO mice (Figure 3.3B), 
indicating that an adaptive immune response is required for the protective effects of 
estrogen depletion.   
Interestingly, ad libitum estradiol supplementation resulted in augmented 
inflammation at tumor (peritoneal) beds (Figure 3.4A).  However, the proportions of 
antigen experienced (CD44+), recently activated (CD69+) tumor-associated CD4 and 
CD8 T cells were significantly higher in OVX tumor-bearing hosts, with corresponding 
decreases in estradiol-supplemented animals (Figure 3.4B).  Accordingly, the frequency 
of T cells isolated from the peritoneal cavity of OVX tumor-bearing mice producing 
Interferon (IFN)-γ in response to cognate tumor antigens was significantly higher than 
those generated by control mice in conventional ELISpot analysis (Figure 3.4C), 
indicative of superior T cell-dependent antitumor immunity.  Consistently, tumor-
associated T cells from E2-treated mice responded significantly worse than either group 
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(Figure 3.4C).  Taken together, these results demonstrate that estrogens accelerate 
ovarian cancer progression, independent of a direct effect on tumor cells, through a 
mechanism that blunts protective antitumor immunity.   
 
Estrogens promote tumor progression in non-ovarian cancer models independent of 
any direct effects on neoplastic cell proliferation 
 The benefits of estrogen depletion were not restricted to ID8-Defb29/Vegf-a 
tumors because the progression of male-derived (Sugiura and Stock 1955), estrogen-
insensitive (Figure 3.5A), Lewis Lung Carcinomas (LLC-1) tumors was also 
significantly delayed in OVX mice, while estradiol supplementation accelerated 
malignant growth, ultimately resulting in decreased survival (Figure 3.5B).  In addition, 
metastatic melanoma B16.F10 cells are not responsive to E2 (Figure 3.6A) in vitro.  
However, high doses of E2 given in vivo increased lung metastasis when tumor cells 
were injected intravenously (Figure 3.6B & C). 
 
ERα signaling in hematopoietic cells enhances ovarian cancer-induced myelopoietic 
expansion  
To determine the mechanism by which estrogen signaling accelerates malignant 
progression, we next investigated differences in the mobilization of immunosuppressive 
cells.  We identified strong estrogen-dependent differences only in the accumulation of 
myeloid derived suppressor cells (MDSCs), both in the spleen (Figure 3.7A & B) and at 
tumor beds (Figure 3.7C & D).  Hence, estrogen treatment increased the percentage and 
total numbers of both Ly6ChighLy6G- myelomonocytic (M-MDSC) and Ly6C+Ly6G+ 
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granulocytic MDSCs (G-MDSC) in tumor-bearing mice, while estrogen depletion 
through OVX significantly decreased their percentage and total numbers both in the 
spleen and at tumor beds (Figure 3.7).   
Estrogens primarily signal through the nuclear receptors ERα and ERβ, the former 
being expressed in virtually all murine hematopoietic cells (Kovats 2015).  Further 
supporting that differences in the ovarian cancer immuno-environment are independent of 
estrogen signaling on tumor cells, we identified ERα expression in MDSCs derived from 
tumor-derived mice (Figure 3.1C).  Importantly, myeloid cells sorted from tumor-
bearing mice were also highly effective at suppressing T cell proliferative responses and 
therefore are true immunosuppressive MDSCs and not merely immature hematopoietic 
cells (Figure 3.8), supporting their role in estrogen-dependent abrogation of antitumor 
immunity.  Interestingly, G-MDSCs from E2-depleted (ovariectomized) mice exhibit 
weaker immunosuppressive potential compared to vehicle or E2-treated mice. 
To confirm that ERα signaling is sufficient to mediate accelerated malignant 
progression, we then challenged ERα-/- and wild type control mice with orthotopic ID8-
Defb29/Vegf-a tumors.  As shown in Figure 3.9A, estradiol supplementation failed to 
accelerate tumor progression in ERα KO hosts but had significant effects in wild type 
controls, indicative that estrogen’s tumor-promoting responses are attributable to ERα 
signaling.  Additionally, ERα KO mice phenocopy OVX WT mice by surviving 
significantly longer than control WT mice.  Most importantly, accelerated tumor growth 
depends on ERα signaling specifically on hematopoietic cells because in response to E2 
treatment, tumors progress significantly faster in lethally irradiated mice reconstituted 
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with wild type bone marrow, compared to identically treated mice reconstituted with 
ERα-deficient bone marrow (Figure 3.9B).   
To determine whether increased MDSC accumulation is sufficient to explain the 
increased tumor progression driven by estrogen signaling, MDSCs were depleted from 
subcutaneous tumor-challenged OVX mice treated with E2 by daily injection of anti-Gr1 
antibody (Figure 3.10).  As expected, tumors in OVX mice treated with E2 and IgG 
control antibody progressed significantly faster than OVX mice treated with vehicle and 
control antibody.  However, in OVX mice treated with E2 and anti-Gr1, tumor 
progression was delayed and identical to OVX mice treated with vehicle and control 
antibody.  Together, these results indicate that ERα signaling on hematopoietic cells 
accelerates malignant progression independent of stimulation of neoplastic cells, through 
a mechanism that results in the mobilization of (ERα+) immunosuppressive MDSCs.   
 
Estrogens signal through ERα on human and mouse myeloid progenitors to boost 
the proliferation of regulatory myeloid cells and enhance their immunosuppressive 
activity  
To rule out that estrogen-dependent myeloid expansion in tumor-bearing mice 
was the result of subtle differences in tumor burden or inflammation, we reconstituted 
lethally irradiated mice with a 1:1 mixture of CD45.2+ERα-/- and (congenic) 
CD45.1+ERα+ bone marrow and challenged them with orthotopic ovarian tumors.  As 
shown in Figure 3.11A & B, a significantly higher percentage (3.6-fold) of total 
(CD11b+Gr-1+) MDSCs arose from ERα+ hematopoietic progenitors, compared to ERα-
deficient cells.  Because reconstitution of total hematopoietic cells occurred at a similar 
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ratio (Figure 3.11A) and MDSCs mobilization took place in the same host under an 
identical milieu, dissimilar ERα-dependent MDSC accumulation can only be attributed to 
cell-intrinsic ERα+ signaling on myeloid precursors.  Notably, we found a preferential 
decrease in the expansion of ERα-deficient M-MDSCs, compared to myeloid cells of the 
granulocytic lineage (Figure 3.11C). 
 To understand how estrogen signaling promotes MDSC expansion, we next 
differentiated MDSCs in vitro by treating naïve wild type (ERα+) BM with GM-CSF and 
IL-6.  As reported (Marigo et al. 2010),  these inflammatory cytokines induced the 
generation of immature myeloid cells that express Ly6G and Ly6C similar to MDSCs 
seen in vivo (Figure 3.12A left).    
Normal cell culture media drives estrogen signaling due to the presence of various 
estrogens in FBS (Briand and Lykkesfeldt 1984) in addition to the estrogenic properties 
of phenol red.  Blocking the estrogen activity of cell culture media with methylpiperidino 
pyrazole (MPP), a selective antagonist of ERα, severely inhibited the expansion of both 
M-MDSCs and G-MDSCs, with a preferential effect on the former (Figure 3.12A left & 
3.12B), similar to in vivo tumor-bearing mice (Figure 3.11C).  In addition, the presence 
of ERα antagonists allowed spontaneous differentiation of CD11c+MHC-II+ dendritic-
like cells (Figure 3.12A right).  Corresponding to in vivo observations (Figure 3.8), 
further addition of estradiol resulted in G-MDSCs that were more potently 
immunosuppressive while abrogation of ERα signaling prevented the acquisition of 
stronger immunosuppressive activity by G-MDSCs (Figure 3.13 top).  In contrast, 
estradiol did not affect the inhibitory activity of M-MDSCs (Figure 3.13 bottom) 
suggesting that the role of estrogens in the accumulation of M-MDSCs is to primarily 
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drive their expansion, although the low yields of BM-MDSCs obtained in the presence of 
estrogen antagonists precludes testing their suppressive activity. 
To support the relevance of ERα signaling in boosting pathological expansion of 
MDSCs, we procured bone marrow from 5 different lung cancer patients, and expanded 
myeloid cells with GM-CSF and IL-6 (Marigo et al. 2010), in the presence of different 
concentrations of an ERα antagonist (MPP).  As shown in Figure 3.14, this system 
results in reproducible expansion of CD11b+CD33+CD15+CD14-MHC-II- granulocytes 
and CD11b+CD33+CD15-/lowCD14+MHC-II- monocytic cells, corresponding to the 
human counterparts of granulocytic and monocytic MDSCs.  Notably, blockade of ERα 
signaling resulted in a dramatic dose-dependent reduction in the expansion of both 
MDSC lineages, both at the level of proportions (Figure 3.14A) and absolute numbers 
(Figure 3.14B).  Together, these data show that estrogen signaling through ERα 
influences myelopoiesis in both mice and humans, ultimately boosting the expansion of 
MDSCs in response to inflammatory signals; contributing to enhance their 
immunosuppressive activity; and blocking their differentiation into MHC-II+ myeloid 
cells, overall promoting malignant progression. 
 
Estrogen signaling enhances STAT3 activation through transcriptional up-
regulation of Janus Kinase 2 (JAK2) and increased total STAT3 expression in 
myeloid progenitors 
 To determine the mechanism by which estrogen signaling promotes MDSC 
mobilization, we focused on the effect of estrogen signaling on STAT3 signaling, which 
plays a major role in regulating myeloid lineage cells and MDSC expansion (Gabrilovich, 
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Ostrand-Rosenberg, and Bronte 2012).  As shown in Figure 3.15A, levels of pSTAT3Y705 
were significantly increased in monocytic and, to a lesser extent, granulocytic MDSCs 
immunopurified from the spleens of advanced ovarian cancer-bearing mice treated with 
E2, compared to OVX mice.  Accordingly, antiestrogen treatment of in vitro BM-MDSCs 
cultures inhibited STAT3 signaling resulting in lower phospho-STAT3 in both M-
MDSCs and G-MDSCs (Figure 3.15B), indicating that pSTAT3 signaling is enhanced by 
estrogen signaling.  Finally, E2 supplementation of cell culture media increased phospho-
STAT3 levels with more obvious activity on M-MDSCs (Figure 3.15B).   
Interestingly, total STAT3 was up-regulated in tumor-bearing host-derived M-
MDSCs, likely as a direct effect of estrogen-driven enhanced IL-6 signaling (Suthaus et 
al. 2012).  Accordingly, antiestrogen drugs down-regulated total STAT3 in BM-derived 
M-MDSC (Figure 3.15A & B).  However, this difference does not appear to be 
transcriptionally regulated, as no differences in STAT3 transcription was observed in M-
MDSCs and statistically significant but non-correlative differences were observed in G-
MDSCs (Figure 3.15C).  The lack of differences in transcription that correspond to 
differences observed in STAT3 protein suggest that turnover of STAT3 protein may 
depend on STAT3 activation.  To test this hypothesis, progenitor cells isolated from WT 
BM were stimulated with 100 ng/mL of IL-6 overnight in the presence of E2 or MPP 
(Figure 3.15D).  Regardless of treatment, IL-6 triggered strong STAT3 activation.  As 
expected, in control cells that did not receive IL-6, no STAT3 activation was observed.  
More importantly however, in these identical cells, which did not receive IL-6, total 
STAT3 levels were also decreased. 
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Because STAT3 activation is triggered by IL-6, which was used for in vitro 
MDSC expansion, we next investigated the role of estrogen signaling on surface 
expression of the IL-6 receptor complex.  Treating BM-MDSCs with E2 or antiestrogens 
did not elicit changes in surface expression of the IL6Rα chain (Figure 3.16 left) or 
Gp130 (Figure 3.16 right), suggesting that estrogen signaling could affect downstream 
mediators.  We therefore focused on kinase activation, such as Jak2 which mediates 
STAT3 phosphorylation, subsequent dimerization, and nuclear translocation following 
cytokine receptor engagement (Murray 2007).  As shown in Figure 3.17 left, estrogen 
supplementation induced transcriptional up-regulation of Jak2 in cytokine-induced bone 
marrow MDSCs of both lineages.  Most importantly, estradiol also induced a 
reproducible Jak2 up-regulation at the protein level (Figure 3.17 right).  Therefore, ERα 
signaling on myeloid precursors drives MDSC expansion by amplifying IL-6 activity 
and, subsequently enhancing JAK-STAT3 signaling.  This occurs downstream of the 
receptor through up-regulation of total STAT3 and increased Jak2 activity. 
 
Estrogen also impacts other components of the tumor immune-environment 
 Finally, to rule out that differences in malignant progression due to the direct 
effect of estrogens on effector T cells, we performed mixed BM chimera experiments in 
which mice received a 1:1 mixture of ERα-/- and congenic wild type BM.  Compared to 
ERα-/- T cells, E2-responsive wild type CD4 and CD8 T cells display a less activated 
phenotype characterized by lower expression of CD44 (Figure 3.18A).  Correspondingly, 
the frequencies of wild type T cells responding to tumor antigens in IFN-γ ELISpot re-
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challenge assays were lower than those of their counterpart ERα-/- T cells, sorted from the 
same microenvironment (Figure 3.18B). 
 To determine the relative importance of these differences in direct ERα signaling 
in T cells, independently of estrogen-dependent MDSC activity, wild type and ERα-/- T 
cell splenocytes were identically enriched for tumor-reactive populations by ex vivo 
priming against tumor lysate-pulsed BMDCs (Y. Nesbeth et al. 2009; Y. C. Nesbeth et al. 
2010), and then adoptively transferred into ovarian cancer-bearing mice at days 7, 14, and 
21.  Confirming previous reports (Y. Nesbeth et al. 2009; Y. C. Nesbeth et al. 2010), both 
wild type and ERα-/- T cells significantly extended survival; however, there was no 
difference between wild type and ERα KO T cells regardless of whether mice were 
treated with E2 (Figure 3.19A).  Therefore, while E2 does have a measurable T cell-
intrinsic effect, this is not sufficient to drive differences in malignant progression, and, 
therefore, its effect on immunosuppressive cells, namely MDSCs, is the main driver 
underlying estrogen-driven tumor acceleration. 
 To further support our hypothesis that estrogen depletion creates a less 
suppressive immune microenvironment as well as to determine its effect on cell-based 
immunotherapies, we challenged WT control or OVX mice with ID8-Defb29/Vegf-a 
tumors and treated them with a single, suboptimal adoptive transfer of antigen-primed T 
cells or antigen-pulsed DCs at day 7 (Figure 3.19B).  Because only one dose of T cells 
was given, T cell administration failed to significantly increase survival as seen in Figure 
3.19A, and there was no combinatory effect with OVX.  DC vaccination did however 
elicit a survival increase.  This effect synergized with OVX resulting in significant 
survival advantage in mice receiving both OVX and DC vaccination compared to mice 
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that only received only one of the treatments (OVX or DCs).  These data further 
emphasize the potentiating effect of E2 on the immunosuppressive tumor 
microenvironment and suggest that combining antiestrogen therapies with 
immunotherapies may be clinically beneficial.  
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Discussion 
Here we show that ERα signaling on myeloid precursors is a major contributor to 
pathological myelopoiesis in cancer, resulting in MDSC expansion and augmented 
immunosuppressive activity.  Accordingly, ovariectomized mice exhibit delayed 
malignant progression upon challenge with different estrogen insensitive tumor models, 
while E2 supplementation has the opposite effects.  Supporting the crucial role of 
spontaneous antitumor immunity in this mechanism, differences in tumor growth 
disappear in T cell-deficient mice. 
Although the role of estrogen signaling in the progression of breast tumors and a 
subset of ovarian cancer patients has been underscored by the clinical use of ER 
antagonists, our results demonstrate that estrogens have a profound effect on antitumor 
immunity and tumor-promoting inflammation, independent of their direct activity on 
tumor cells.  Our data therefore provide novel mechanistic insight into how enhanced 
estrogenic activity contributes to malignant progression in established tumors.  
Furthermore, our data support that novel antiestrogen drugs that, unlike tamoxifen (Gallo 
and Kaufman 1997),  have no agonistic effects  on non-breast cell types, may have 
benefits in a wide range of cancers in pre-menopausal women, independently of the 
expression of ERs in tumor cells.  Therefore, antiestrogens, especially when used as an 
adjuvant therapy, may synergize with immunotherapies such as checkpoint inhibitors to 
significantly extend survival.  Thus, while bilateral oophorectomy is standard in ovarian 
cancer treatment, our data suggest that ER- breast tumors and other malignancies in at 
least female cancer patients in their reproductive age could be delayed by specifically 
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blocking ERα in a systemic manner, especially if complementary immunotherapies are 
implemented as adjuvant therapy. 
Our results also have implications to understand gender-dependent differences in 
tumor initiation and malignant progression in different malignancies.  This may be 
particularly relevant in BRCA1-mutation carriers, where augmented estrogenic signal has 
been recently demonstrated (Widschwendter et al. 2013).  Furthermore, ERα expression 
is regulated by BRCA1-dependent ubiquitination (Eakin et al. 2007), so that cancer-
predisposing heterozygous BRCA1 mutations could result in increased ER expression, 
and therefore increase estrogen activity.  Whether mobilization of MDSCs in the context 
of additional inflammatory signals contributes to tumor initiation in BRCA1 mutation 
carriers demands further experimental proof, but our study suggests this as a likely 
pathogenic mechanism.   
This study finally contributes to the understanding of the complexity of factors 
deregulating myelopoiesis (and therefore antigen presentation) in virtually all solid 
tumor-bearing hosts.  Our data indicate that ERα signaling has a triple effect on myeloid 
bone marrow progenitors by altering pSTAT3 signaling, which drives both expansion and 
increased survival in these cells (Gabrilovich, Ostrand-Rosenberg, and Bronte 2012): on 
the one hand, estrogens up-regulate JAK2, which mediates STAT3 phosphorylation, as 
well as total STAT3 itself.  Therefore, estrogenic activity prepares the bone marrow for 
acute expansion of myeloid precursors, but estrogen-dependent mobilization of MDSCs 
only occurs in the presence of direct inflammatory signals that activate JAK kinases 
(typically, IL-6), and not necessarily in a cyclic manner during the menstrual cycle.  
Accordingly, incubation with E2 alone does not result in myeloid expansion in vitro, 
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while combinations of IL-6, GM-CSF and E2 drive MDSC mobilization to a much 
greater extent than cytokines alone (Figure 1.2).  These mechanisms appear to be 
important during pregnancy, where estradiol also drives the expansion and activation of 
MDSCs (Pan et al. 2016), but our study demonstrates their relevance in the pathogenesis 
of women’s malignancies.   
In summary, our study unveils the role of estrogen signaling in pathological 
myelopoiesis, and supports that more specific antiestrogen drugs could complement 
emerging immunotherapies to significantly extend the survival of cancer patients, 
independently of the expression of ERs in tumor cells. 
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Figures 
Figure 3.1 
 
Figure 3.1: Estrogen receptor α is expressed by non-neoplastic cells in the ovarian tumor 
microenvironment 
 
A, Immunohistochemistry of human ovarian tumor sections were stained for ERα (scale 
bar indicates 10 µm).  Positive tumors (left) express ERα in neoplastic as well as normal 
cells found in the tumor microenvironment.  In negative tumors (right), ERα expression 
can only be found in tumor-infiltrating cells.  B, Hematopoietic myeloid (CD45+CD11b+) 
and non-myeloid (CD45+CD11b-) cells were FACS-isolated from human ovarian tumors 
or bone marrow (BM) and ERα expression was confirmed by reverse transcription PCR.  
MCF-7 and MDA-MB-231 cDNA served as a positive and negative controls, 
respectively.  Water was used for a no template control (NTC).  C, Via western blot, 
mouse ovarian ID8-Defb29/Vegf-a tumor cells do not express ERα, while MDSCs 
(CD11b+Gr-1+) isolated from in vivo ID8-Defb29/Vegf-a tumors do.  
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Figure 3.2 
 
 
 
Figure 3.2: ID8-Defb29/Vegf-a proliferation is unaffected by direct estrogen signaling 
 
ID8-Defb29/Vegf-a cells grown in vitro in estrogen-depleted steroid-free media (SFR10) 
do not respond to E2 supplementation, unlike the known E2-responsive control MCF-7 
cells (left).  Similarly, antiestrogen (fulvestrant) treatment of cells grown in estrogen 
containing normal media had no effect (right).  Proliferation was determined by MTS 
assay.  Proliferation is expressed in arbitrary units (A.U.) calculated by normalizing the 
absorbance of each condition to the average absorbance of the cell type’s vehicle control.  
Significant differences between vehicle and treated samples were determined by 
confirming Gaussian distribution and subsequent T-testing.  Asterisks (*) indicate 
significant difference (p < 0.05) from vehicle-treated cells. 
  
55 
 
Figure 3.3 
 
 
 
Figure 3.3: Estrogen depletion increases ID8-Defb29/Vegf-a survival, but only in 
immunocompetent mice 
 
A, Estrogen-depleted, ovariectomized (OVX) wild type mice survive significantly longer 
than control sham-operated mice challenged with i.p. ID8-Defb29/Vegf-a tumors.  B, 
OVX fails to increase survival in immunodeficient RAG1 KO mice.  Experiments were 
repeated three times with n=5 mice per group each time.  Significance was calculated via 
Log-rank testing with p < 0.05 deemed significant, and asterisk (*) indicates significant 
difference between WT+Vh and other treatment groups.  Representative data is shown. 
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Figure 3.4 
 
 
 
Figure 3.4: E2 decreases the ability of endogenous T cells to respond to tumor antigens 
 
A, Tumor bearing mice treated with E2 have significantly increased T cell accumulation 
compared to vehicle or OVX treated mice.  N=5 mice per group.  B, The proportions of 
activated (CD44+CD69+) tumor-associated CD4 and CD8 T cells is higher in OVX 
compared to E2-treated mice.  C, A larger proportion of T cells isolated from OVX mice 
are able to respond to cognate tumor antigens in ELISpot re-challenge assays compared 
to Vh or E2 treated mice.  Gaussian distributions were determined by Kolmogorov-
Smirnoff tests.  Significance between treatment groups was determined by T-tests or 
Mann-Whitney tests.  Asterisk (*) indicates p < 0.05. 
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Figure 3.5 
 
 
Figure 3.5: Estrogens affect LLC-1 tumor progression independent of direct cancer-cell 
intrinsic signaling 
 
A, LLC-1 cells grown in E2-depleted SFR10 media do not increase proliferation in 
response to E2, unlike E2-responsive MCF-7 cells (left).  Proliferation of LLC-1 cells 
grown in normal E2-containing media are not inhibited by the antiestrogen fulvestrant, 
unlike MCF-7 cells (right).  Proliferation was determined by MTS assay and calculated as 
arbitrary units (A.U.) by normalizing absorbance to the average absorbance of vehicle-
treated cells.  B, OVX significantly impairs progression in intraperitoneal (IP) and 
subcutaneous (SQ) tumors, while E2 treatment significantly increases progression in SQ 
LLC-1.  Asterisks (*) indicate significant difference (p < 0.05) from vehicle conditions, 
calculated by T-testing.   
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Figure 3.6 
 
Figure 3.6: Estrogens affect B16.F10 metastasis via cancer-cell extrinsic mechanisms 
 
A, B16.F10 cells fail to respond to E2 or antiestrogen (MPP) treatment in vitro.  B, E2 
treatment increases the number of tumor foci found in lungs of mice (n=5 per group) 
injected intravenously with B16.F10 cells after 2 weeks, as determined by hematoxyline 
and eosin staining.  C, Quantification of number of tumor foci in lungs.  Asterisk (*) 
indicates significant difference from vehicle calculated by T-test, p < 0.05. 
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Figure 3.7 
 
 
Figure 3.7: E2 increases MDSC accumulation in tumor-bearing mice 
 
A & B, E2 increases the proportion and total numbers of M- and G-MDSCs in the 
spleens of ID8-Defb29/Vegf-a intraperitoneal tumor bearing female mice (n=5 mice per 
group).  C & D, Similar increases in MDSCs are seen in the peritoneal wash of these 
mice.  Significance was determined by T-tests.  Double asterisks (*/*) indicate significant 
difference (p < 0.05) in both M- and G-MDSCs between treatment groups.  Single 
asterisk (*) indicates significant difference (p < 0.05) in G-MDSCs between groups. 
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Figure 3.8 
 
 
 
Figure 3.8: MDSCs from tumor-bearing mice are immunosuppressive 
MDSCs isolated from the peritoneal wash of i.p. ID8-Defb29/Vegf-a tumor bearing mice 
were co-cultured with naïve T cells activated with anti-CD3/28 beads, and proliferation 
was determined via dilution of CellTrace Violet after 3 days.  M-MDSCs from Vh, E2, 
and OVX mice are all potently suppressive, but G-MDSCs from OVX mice are far less 
suppressive than those from Vh and E2 treated mice.    
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Figure 3.9 
 
Figure 3.9: Hematopoietic ERα activity is required for maximal response to E2 
 
A, WT and ERα KO mice were treated with vehicle or estrogen and challenged with i.p. 
ID8-Defb29/Vegf-a tumors.  Results shown are pooled from three independent 
experiment using n=5 mice per group.  B, Following lethal irradiation, mice were 
reconstituted with WT or KO BM, treated with Vh or E2, and challenged with i.p. tumors 
(n=5 mice per group).  Significance between groups was determined by Log-rank test. 
Asterisk (*) indicates p < 0.05. 
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Figure 3.10 
 
 
      Days 
Figure 3.10: MDSCs are required for E2 to increase tumor progression 
Ovariectomized WT C57BL/6 mice were subcutaneously injected with 1X104 A7C11 
(syngeneic p53 null, oncogenic Kras-driven) breast cancer cells in matrigel and treated 
with vehicle (0.1% EtOH) or E2 (10 µM) drinking water.  Starting two days after tumor 
challenge, mice received daily injections of 250 µg of isotype control IgG or anti-Gr1 
antibody (RB6-8C5).  Tumors were measured twice per week for 15 days.  Statistically 
significant differences between mean tumor volumes was determined by T-test once 
normal distribution was confirmed via Kolmogorov-Smirnov testing.  Significant 
differences were defined using a p < 0.05, and asterisks (**) indicates significant 
differences between the OVX+E2+irrelevant IgG group (n=5) and each of the 
OVX+E2+anti-Gr1 (n=5) and OVX+Vh+iIgG groups (n=5), tested separately. 
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Figure 3.11 
 
 
 
Figure 3.11: Cell-intrinsic ERα signaling increases the proportion of WT relative to ERα 
KO MDSCs in mixed BM chimeras 
 
A & B, Mice reconstituted with a 1:1 mix of WT CD45.1 and KO CD45.2 BM equally 
repopulate lethally irradiated hosts.  Within the same hosts challenged with ID8-
Defb29/Vegf-a intraperitoneal tumors, WT BM was significantly more effective at 
producing CD11b+Gr-1+ splenic MDSCs than KO BM.  C, In an independent mixed BM 
chimera experiment, WT BM results in proportionally (as a percent of CD11b+MHC-II- 
cells) more M-MDSC in the spleen compared to KO BM.  Significance was determined 
by Mann-Whitney testing.  Asterisk (*) indicates p < 0.05. 
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Figure 3.12 
 
 
Figure 3.12: In vitro mouse BM-MDSDC differentiation is skewed towards a DC-like 
phenotype upon ERα inhibition 
 
A, The differentiation of WT mouse BM cultured in 40 ng/mL GM-CSF + 40 ng/mL IL-
6 into M- and G-MDSCs is impaired in the presence of the ERα antagonist MPP (left).  
Instead of becoming MDSCs, MPP skews myeloid differentiation in favor of 
CD11c+MHC-II+ DC-like cells (right).  B, Total cell yields of M- and G-MDSCs are 
decreased when treated with MPP.  Significance was determined by T-tests.  Asterisk (*) 
indicates p < 0.05. 
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Figure 3.13 
 
 
Figure 3.13: While all BM-MDSCs are immunosuppressive, E2 is required for maximal 
G-MDSC suppression 
 
BM-derived MDSCs were co-cultured with CellTrace Violet labeled T cells activated 
with anti-CD3/CD28 beads at different ratios.  T cell proliferation was determined by 
CellTrace Violet dilution after 3 days.  G-MDSCs from E2-augmented cultures were able 
to effectively suppress T cell proliferation down to a 1:16 ratio of MDSCs to T cells 
while Vh BM-MDSCs required a 1:4 ratio.  MPP G-MDSCs had only marginal effects on 
T cell proliferation even at a 1:4 ratio (top).  M-MDSCs from Vh and E2 treated cultures 
were equally suppressive (bottom). 
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Figure 3.14 
 
 
Figure 3.14: Human BM-MDSC expansion is impaired by antiestrogen treatment 
 
A & B, Human BM from lung cancer patients was cultured in normal media containing 
40 ng/mL GM-CSF + 40ng/mL IL-6 resulting in M-MDSCs (CD11b+CD33+CD14+) and 
G-MDSCs (CD11b+CD33+CD15+).  Treating with increasing doses of MPP significantly 
impaired the total number of M- and G-MDSCs produced in these cultures without 
decreasing the overall proportion of viable cells indicating that the effects of MPP are not 
merely cytotoxic.  Significance was determined by T-tests comparing each treatment 
groups to the vehicle control group.  Asterisk (*) indicates p < 0.05. 
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Figure 3.15 
 
 
 
Figure 3.15: Estrogen signaling is required for optimal STAT3 activation in MDSCs 
 
A, MDSCs were isolated from the peritoneal cavity and spleen of ID8-Defb29/Vegf-a 
intraperitoneal tumor bearing mice treated by OVX or E2 and analyzed via western blot.  
E2 increased STAT3 activation in in vivo MDSCs.  B, In vitro cytokine derived BM-
MDSCs also require ERα signaling for optimal STAT3 activation.  Additionally, in M-
MDSCs, total STAT3 is decreased by estrogen inhibition.  C, Quantitative real time PCR 
of M- and G-BM-MDSCs fail to show changes in STAT3 transcription that correspond 
with protein levels.  Therefore, regulation of STAT3 likely occurs post-translationally.  
D, BM progenitor cells stimulated overnight with a high dose of 100 ng/mL IL-6 are able 
to activate STAT3 regardless of E2 or MPP treatment.  Without IL-6, these cells do not 
activate STAT3, and total STAT3 levels are diminished.  Significance compared to 
vehicle was determined by Mann-Whitney testing.  Asterisk (*) indicates p < 0.05. 
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Figure 3.16 
 
 
 
Figure 3.16: IL-6 receptor is not decreased by antiestrogen treatment 
 
BM-MDSCs were stained for surface expression of the IL6Rα chain (CD126) and Gp130 
(CD130).  Instead of decreasing the MFIs of IL6Rα and Gp130 in MPP treated cells, 
slight increases were observed.  E2 had no effect on IL6Rα and Gp130 compared to 
vehicle. 
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Figure 3.17 
 
 
 
Figure 3.17: Jak2 expression is increased by E2 treatment 
 
Compared to vehicle, BM-MDSCs treated with E2 significantly up-regulate Jak2 at both 
the RNA (left) and protein level (right).  Significant differences compared to vehicle was 
determined by Mann-Whitney testing.  Asterisk (*) indicates p < 0.05. 
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Figure 3.18 
 
 
 
Figure 3.18: ERα has cell-intrinsic inhibitory effects on tumor infiltrating T cells 
 
A, Mice were reconstituted with a 1:1 mix of WT CD45.1 and ERα KO CD45.2 BM and 
challenged with intraperitoneal ID8-Defb29/Vegf-a tumors.  WT T cells within the same 
tumor microenvironment had a less activated phenotype compared to their counterpart 
KO T cells.  B, WT and KO T cells sorted from the tumor microenvironment were 
subsequently re-stimulated with tumor antigen-pulsed BMDCs in ELISpot assay.  A 
significantly higher proportion of KO T cells responded to cognate antigens compared to 
WT T cells by producing IFN-γ.  Significance was determined by T-testing.  Asterisk (*) 
indicates p < 0.05. 
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Figure 3.19 
 
Figure 3.19: The overall effect of E2 on the immune microenvironment is more 
important than its direct effect on T cell inhibition 
 
A, Tumor challenged WT mice treated with vehicle or E2 received multiple doses of 
antigen-primed WT or ERα KO T cells resulting increased survival (n=5 mice per group).  
However, irrespective of E2 treatment, WT and KO T cells were equally effective.  B, 
Tumor challenged WT vehicle or OVX treated mice were given cell-based 
immunotherapies in the form of antigen-primed T cells or DC vaccination.  No 
significant survival advantage was observed in OVX mice receiving T cells compared to 
OVX control mice; however, OVX mice receiving DC vaccination did survive 
significantly longer compared to OVX control mice.  Significance was determined by 
Log-rank testing with p< 0.05 deemed significant.  Asterisks (*) indicate increased 
survival compared to non-OVX control mice and hash (#) indicates increased survival 
compared to OVX control mice.   
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Conclusions 
This work demonstrates that estrogens have an important role in shaping the 
tumor microenvironment.  In the absence of estrogen signaling, antitumor T cells are able 
to significantly delay tumor progression.  While estrogen signaling has direct effects on T 
cells, including impairing Th1 CD4 differentiation, these effects do not account for all of 
estrogen’s effects on tumor progression, as E2 treatment is capable of accelerating tumor 
progression in T cell-lacking RAG1 KO mice.  This work shows for the first time, that 
estrogen signaling increases the accumulation of MDSCs, which accelerate tumor 
progression through a variety of mechanisms that include suppressing T cell responses.  
The mechanism of E2 on MDSCs appears to be increased the JAK2-STAT3 signaling via 
increased JAK2 expression.  This work also demonstrates that estrogen depletion is 
capable of augmenting the benefit of DC vaccine-based immunotherapy.  Therefore, 
antiestrogen therapies have clinical potential, especially in combination with emerging 
immunotherapies. 
Estrogens are capable of directly influencing multiple “hallmarks of cancer” 
(Figure 1.1), such as cell proliferative and anti-apoptotic mechanisms.  As a result, 
antiestrogen therapies, such as tamoxifen, have been used extremely effectively as 
adjuvant therapy for ER+ breast cancer.  I believe that this success has actually limited 
consideration of estrogen in other estrogen-independent tumors by focusing the field 
solely on how these early antiestrogen drugs affects neoplastic cells.  In a few small 
clinical trials conducted in the relatively nascent stages of estrogen therapy, tamoxifen 
was used as salvage therapy in non-ER+ breast cancers, such as ovarian cancer.  
However, partly due to the fact that these are such late stage treatment-resistant tumors, 
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little clinical benefit was observed.  This may be addressed by using antiestrogens earlier 
in cancer treatment, especially immediately following surgical resection, at which point 
there is clinically no “evidence of disease.”   
Our findings in preclinical models that estrogen depletion can increase antitumor 
immunity suggest that there may only be a limited window, such as in early tumor 
immune responses, where antiestrogen therapy can be effective.  However, with the 
advent of immunotherapies, especially cell-based immunotherapies, it may be possible to 
re-open or extend this window.  It is also important to note that clinical trials have 
demonstrated that antiestrogen therapies are generally well-tolerated, which makes them 
attractive candidates to be combined with other therapies.   
Another problem in early clinical trials with antiestrogens has been the reliance on 
tamoxifen.  Tamoxifen is a selective estrogen receptor modulator (SERM) meaning that 
depending on specific cell type, tamoxifen can either act as an agonist or antagonist.  
Therefore, tamoxifen may actually serve as an agonist in non-neoplastic cell responses to 
tumors.  Pure antagonists may therefore be an attractive option in future studies and 
treatments centered on inhibiting estrogen signaling. 
Further complicating matters, it is now recognized that there are multiple 
receptors for estrogen, which are dynamically expressed and mediate different, at times 
contradictory, responses.  Therefore, non-specific targeting of estrogen signaling using 
pan-inhibitors, like fulvestrant, or targeting estrogen production, by inhibiting aromatase 
using drugs like letrozole, may have variable effects.  Newer, subtype specific 
antagonists may therefore provide more consistent effects. 
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Our work supports findings by others that the effect of estrogen signaling on 
specific cells is context dependent.  It is now clear that the direct proliferative responses 
of breast and endometrial epithelial cells triggered by estrogen stimulation alone is rare.  
Instead, the estrogen signaling network interacts with other signaling networks, such as 
cytokine-induced activation, resulting in attenuated or increased cytokine responses, or 
even completely novel effects.  In our work, it is important to acknowledge that most of 
the data were generated using one model of ovarian cancer, ID8-Defb29/Vegf-a, which, 
like all tumors, acquires a unique microenvironment.  While this model does recapitulate 
key features of ovarian cancer, it is still just one model.  Therefore, other tumor models 
may elicit different milieu of inflammatory cytokines, which may alter the effect of E2 on 
tumor progression.  Nevertheless, our data, showing the ability of E2 to accelerate LLC-1 
and B16.F10 models independent neoplastic cell proliferation, in combination with 
literature, supporting the role of estrogen in increasing myeloid and humoral immune 
responses, support our overall hypothesis that estrogen is capable of promoting malignant 
progression in a variety of tumor settings. 
This work is also particularly enlightening when considering how pervasive yet 
unacknowledged estrogens are in research and in health.  Typical cell culture media is 
highly estrogenic due to the presence of FBS and phenol red.  This may underlie 
anecdotal reports that cell behavior tends to vary depending on company and batch of 
media used.  Most mouse studies use ovary-intact females of reproductive age fed a 
standard diet containing phytoestrogens.  Additionally, estrogen levels fluctuate 
according to menstrual cycle.  Our data suggest that these are important factors capable 
of influencing tumor progression.  Indeed, it is already well known that certain preclinical 
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tumor models progress differently in male versus female mice.  Estrogens are likely a key 
reason for this sexual dimorphism. 
 
Future Directions 
 This work demonstrates that STAT3 activation in myeloid cell differentiation is 
affected by ERα signaling; however, a number of questions revolving around this 
mechanism still remain unanswered.  ERα, as a transcription factor, binds DNA estrogen 
response elements (EREs) or may be tethered to non-ERE DNA.  It remains to be 
determined which specific genes are being directly regulated by ERα.  This can be 
addressed by Chromatin Immunoprecipitation Sequencing (ChIP-seq).  Challenges to this 
approach lie in finding a ChIP-grade antibody capable of specifically pulling down 
mouse ERα, in addition to acquiring enough cells.   
 Another important piece of data from our study that raises unanswered questions 
was the finding that the immunosuppressive potential of G-MDSCs positively correlates 
with estrogen treatment.  G-MDSC from MPP treated cultures were weakly suppressive 
while G-MDSCs from E2 augmented cultures were more highly suppressive.  It is 
unclear how E2 is affecting G-MDSC suppression.  For example, E2 may increase 
arginase production, the release of reactive oxygen or nitrogen species, or other 
immunosuppressive cytokines.  More complete transcriptome profiling would provide 
major insight into how E2 perturbs G-MDSC function. 
 In addition to ERα, additional estrogen receptors, ERβ and GPER, are expressed 
by leukocytes.  A major limitation of this work was the sole focus on ERα.  Especially in 
vivo it is likely that ERβ and GPER are partially responsible for the overall tumor-
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promoting response of E2.  Knockout mice and pharmacological inhibitors exist that 
would allow further study in this direction.  In particular, generating mixed BM chimeras 
using ERβ KO mice would allow study of hematopoietic tumor microenvironment cell-
intrinsic effects directly attributable to ERβ status. 
Additionally, all of these estrogen receptors have been reported to be expressed 
by other immune cells not directly examined in this study, such as NK and B cells.  It is 
also likely that estrogens affect their function further contributing to the tumor-promoting 
effect of E2 treatment in vivo.     
While there remain many unanswered questions, we have found a novel 
mechanism for E2-accelerated tumor progression independent of neoplastic cell 
signaling.  This finding has important implications in clinical practice as well as basic 
science research due to the nearly ubiquitous, but largely ignored presence of estrogenic 
molecules in health and research.  By demonstrating potent tumor promotion via altered 
responses to tumor-derived inflammation, our work emphasizes that estrogen is a 
multifaceted and crucial factor to consider in a wide variety of clinical settings and 
laboratory studies.  
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